Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma

Figure 1 Circulating and tumor-infiltrating CD33⁺HLA-DR^- myeloid-derived suppressor cells in colorectal carcinoma patients. A: CD33⁺HLA-DR^- myeloid-derived suppressor cells (MDSCs) were present in the peripheral blood of colorectal carcinoma (CRC) patients and healthy donors, as well as in CRC tumor tissues; B: The percentage of CD33⁺HLA-DR^- MDSCs was significantly increased in the blood and tumor tissues of CRC patients (^aP < 0.05). PBMCs: Peripheral blood mononuclear cells.

Figure 2 Phenotypic analyses of CD33⁺HLA-DR^- myeloid-derived suppressor cells in colorectal carcinoma patients and healthy donors. A: Cell surface markers of peripheral blood myeloid-derived suppressor cells (MDSCs), obtained by gating on the CD33⁺HLA-DR^- subset, were detected in colorectal carcinoma (CRC) patients; B: Percentages of cells positive for various markers on the CD33⁺HLA-DR^- subset in healthy donors (HD) and CRC patients (^aP < 0.05).